Mercados españoles cerrados

I-Mab (IMAB)

NasdaqGM - NasdaqGM Precio en tiempo real. Divisa en USD
Añadir a la lista de favoritos
1,87000,0000 (0,00%)
A partir del 02:18PM EDT. Mercado abierto.

I-Mab

New Bund Center
55th Floor 555 West Haiyang Road Pudong District
Shanghai 200124
China
86 21 6057 8000
https://www.i-mabbiopharma.com

Sector(es)Healthcare
SectorBiotechnology
Empleados a tiempo completo

Ejecutivos clave

NombreTítuloPagaEjecutadoAño de nacimiento
Mr. Raj KannanCEO & DirectorN/AN/A1964
Dr. Jerry WangCo-Founder & Chief Scientific OfficerN/AN/AN/A
Mr. Skelton JosephChief Financial OfficerN/AN/AN/A
Mr. Tianyi ZhangVice President of Investor RelationsN/AN/AN/A
Mr. Cheng LiChief Legal OfficerN/AN/A1984
Ms. Gigi Qi FengChief Communications OfficerN/AN/A1981
Dr. Weiming Tang Ph.D.Executive VP of Global Business Development & Chief Business OfficerN/AN/A1966
Dr. Fernando J. Salle´s Ph.D.Senior VP and Head of U.S. & EU Business DevelopmentN/AN/AN/A
Claire XuHead of US siteN/AN/AN/A
Dr. John Hayslip M.D.Chief Medical OfficerN/AN/A1977
Los importes son a partir de y los valores de compensación son para el último año fiscal que finaliza en esa fecha. Paga es el salario, las bonificaciones, etc. Ejecutado es el valor de las opciones ejecutadas durante el año fiscal. Divisa en USD.

Descripción

I-Mab, a clinical stage biopharmaceutical company, discovers, develops, and commercializes biologics to treat cancer and autoimmune disorders. It is developing Felzartamab, a CD38 antibody that is in Phase 1b/2a for patients with membranous nephropathy; Eftansomatropin alfa, a long-acting growth hormone, which has completed Phase 3 clinical trials to treat pediatric growth hormone deficiency; Efineptakin alfa, a recombinant human IL-7 that is in Phase 2 for cancer treatment-related lymphopenia and cancer immunotherapy; and Lemzoparlimab, a CD47 monoclonal antibody that has completed Phase 2 clinical trial. Its product candidates also includes TJ210, a monoclonal antibody against human C5aR1 that is in Phase 1 for the treatment of cancers and autoimmune; Uliledlimab, a CD73 antibody, which is in Phase 2 clinical trials for treating solid tumors and oncology; TJ-L14B, a PD-L1-based tumor-dependent T-cell engager for solid cancers; Givastomig, a tumor-dependent T cell engager for gastric and other cancers; TJ-L1IF, a PD-L1/IFN-a antibody-cytokine fusion protein for PD(L)-1 resistant tumors; and TJ-C64B, a bispecific antibody for ovarian and other cancers. The company has strategic collaboration agreement with PT Kalbe Genexine Biologics; AbbVie Ireland Unlimited Company; Jumpcan Pharmaceutical Group; Sinopharm Group Co. Ltd.; and Roche Diagnostics. I-Mab was founded in 2014 and is headquartered in Shanghai, the People's Republic of China.

Gobierno corporativo

El ISS Governance QualityScore de I-Mab, a día N/A, es N/A. Las puntuaciones base son Auditoría: N/A; Tablero: N/A; Derechos de los accionistas: N/A; Compensación: N/A.

Puntuación de gobierno corporativo cedida por Institutional Shareholder Services (ISS). Las puntuaciones indican un rango decil relativo al índice o región. Una puntuación decil de 1 indica un menor riesgo de gobierno, mientras que un 10 indica un riesgo de gobierno superior.